Roflumilast and selective PDE4 inhibitors have demonstrated a broad spectrum of anti-inflammatory effects on chronic respiratory diseases including asthma, asthma-COPD overlap syndrome, and COPD with comorbidities. Further well-designed clinical studies will be helpful. The gene discussed is PDE4A; the disease is asthma.